Skip to main content

Advertisement

Fig. 2 | Respiratory Research

Fig. 2

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Fig. 2

Individual IgG antibody titres to H. pylori (HP) CagA antigen in plasma of COPD patients at 0 (baseline) and 12 months. AZ, Azithromycin; PL, Placebo. The horizontal lines denote arithmetic means for individual groups. The differences in antibody concentrations within an individual patient between two time points were compared using a paired t-test. During follow-up, there was a significant decrease in antibody level from baseline (mean ± SEM) in both the HP+/AZ group (−35.42 ± 9.41; p < 0.001) and the HP+/PL group (−45.91 ± 11.83; p < 0.001) over the year. There was no significant increase in antibody level from baseline in the HP-/AZ group (1.38 ± 1.07; p = 0.198). In contrast, there was a significant increase in the HP-/PL group (3.21 ± 1.56; p = 0.041)

Back to article page